Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors

SAN DIEGO, Aug. 11, 2022 /PRNewswire/ — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Jane Chung, R.Ph., as an independent member to its Board of Directors. “Ms. Chung’s unique…

Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks